Search research articles
Contact Us
Filters
Showing results (191-200 of 201) with videos related to
Page
of 21
Sort By:
Human Molecular Genetics
|
July 13, 1999
Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion
C De Jonghe, M Cruts, E A Rogaeva, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Christopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
Bone Marrow Transplantation
|
January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
Ruth M de Tute, Gordon Cook, David A Cairns, et al.
The Lancet. Oncology
|
June 21, 2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Gordon Cook, Cathy Williams, Julia M Brown, et al.
Translational Psychiatry
|
February 3, 2016
Exome sequencing in dementia with Lewy bodies
M J Keogh, M Kurzawa-Akanbi, H Griffin, et al.
Journal of Medical Genetics
|
March 29, 2005
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration
A M Pittman, A J Myers, P Abou-Sleiman, et al.
Nature Genetics
|
July 5, 2001
Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease
A R Curtis, C Fey, C M Morris, et al.
The Lancet. Haematology
|
July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
Sam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
British Journal of Haematology
|
February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 201) with videos related to
Sort By:
Page
of 21
Human Molecular Genetics
|
July 13, 1999
Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion
C De Jonghe, M Cruts, E A Rogaeva, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Christopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
Bone Marrow Transplantation
|
January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
Ruth M de Tute, Gordon Cook, David A Cairns, et al.
The Lancet. Oncology
|
June 21, 2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Gordon Cook, Cathy Williams, Julia M Brown, et al.
Translational Psychiatry
|
February 3, 2016
Exome sequencing in dementia with Lewy bodies
M J Keogh, M Kurzawa-Akanbi, H Griffin, et al.
Journal of Medical Genetics
|
March 29, 2005
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration
A M Pittman, A J Myers, P Abou-Sleiman, et al.
Nature Genetics
|
July 5, 2001
Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease
A R Curtis, C Fey, C M Morris, et al.
The Lancet. Haematology
|
July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
Sam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
British Journal of Haematology
|
February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Page
of 21